Document:

khinesab.htm

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    SCIENTIFIC
ADVISORY BOARD

    CONSULTING
AGREEMENT

    

    

    This Scientific Advisory Board
Consulting Agreement (the “Agreement”)
is made as of this ______ day of March, 2009, between Shrink Technologies, Inc.,
a California corporation (the "Company"),
and Dr. Michelle Khine (the "Consultant")
and shall be effective upon execution by the Company and the Consultant (the
"Effective
Date"). The Company and the Consultant are collectively referred to
herein as the “Parties.”

    

    The Consultant is the principal
inventor of the technology which the Company has licensing rights to and has
been involved in scientific research in fields of particular interest to the
Company.  The Company wishes to retain the Consultant in a consulting
capacity and as a member of one or more panels of the Company's Scientific
Advisory Board (the “SAB”)
and the Consultant desires to perform such consulting services. Accordingly, the
Parties agree as follows:

    

    1.           Services.  The
Consultant will advise the Company's management, employees and agents, at
reasonable times, in matters related to the relevant field of interest (“Field of
Interest”), as requested by the Company and set forth in Exhibit A
attached hereto.Consultant will provide consulting services, which shall amount
to not more than twenty (20) days per annum, as reasonably requested by the
Company and as the Consultant’s schedule permits. Consultation may be sought by
the Company over the telephone, in person, at the Company's offices or another
reasonable location or through written correspondence, and will involve
reviewing activities and developments in the Field of
Interest.  Additionally, Consultant may be requested to attend, to the
extent Consultant’s schedule permits, one or more in person meetings with other
members of a Panel or the SAB, upon reasonable notice being given to the
Consultant, in keeping with the terms of this Agreement.

    

    2.           Term and
Termination.  The term of this Agreement will begin on the
Effective Date of this Agreement and will end on the four year anniversary
(based on a 360 day year containing four (4) ninety (90) day quarterly periods)
of this Agreement or upon earlier termination as provided below (the "Term");
provided that the Term may be renewed, by mutual assent by the Parties, for
successive one-year periods. This Agreement may be terminated at any time upon
sixty (60) days written notice by either party.  The Consultant
agrees, following the termination of this Agreement or upon earlier request by
the Company, to promptly return all drawings, tracings, and all visual or
written materials in the Consultant’s possession that were supplied by the
Company in conjunction with the Consultant’s consulting services under this
Agreement, or generated by the Consultant in the performance of consulting
services under this Agreement.

    

    3.           Compensation.  Immediately following an
acquisition transaction with AudioStocks, Inc. (“AUIO”), a Delaware corporation
(NASDAQ: AUIO), exclusive of the Signature Bonus (the “Signature
Bonus” described below) the right, title and interest in the Compensation
discussed in this Section 3 shall be earned, vest and be due and payable, during
the Term, in equal quarterly amounts, on the first day of the quarterly period
immediately subsequent to a quarterly period in which this Agreement was
effective.  The Consultant shall be compensated for services rendered
as set follows:

    

    3.1           200,000
common shares of AUIO as a Signature
Bonus, earned on the 180th day of
the Term.

    

    3.2           Beginning
on the first day of every quarterly period which this Agreement is effective
(“Option
Exercise Start”) and ending twenty-four months thereafter (“Option
Exercise End”), for any such respective quarterly period, Consultant
shall have the right to purchase up to 25,000 restricted common shares (“Quarterly
Allotment”) of the Company’s stock at the closing market price for the
Company’s common shares on the first day such an option may be exercised (the
“Exercise
Price”).  Consultant understands that any restricted shares,
and any securities issued in respect thereof, shall bear the following
legend:

    

    “THE
SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE
SECURITIES ACT OF 1933, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A
VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF.  THESE
SECURITIES MAY NOT BE OFFERED, SOLD, TRANSFERRED OR OTHERWISE DISPOSED OF UNLESS
REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND ANY APPLICABLE
STATE SECURITIES LAWS OR AN EXEMPTION FROM SUCH REGISTRATION IS
AVAILABLE.

    

    3.3           The
Company shall reimburse the Consultant for all pre-approved and reasonable
expenses incurred in the performance of this Agreement.

    

    4.           Certain Other
Contracts.  The Consultant will not disclose to the Company any
information that the Consultant is obligated to keep secret pursuant to an
existing confidentiality agreement with a third party, and nothing in this
Agreement will impose any obligation on the Consultant to the
contrary.  The consulting work performed hereunder will not be
conducted on time that is required to be devoted to any other third party. The
Consultant shall not use the funding, resources and facilities of the any other
third party to perform consulting work hereunder and shall not perform the
consulting work hereunder in any manner that would give any third party rights
to the product of such work.  The Consultant has disclosed and, during
the Term, will disclose to the President of the Company any conflicts between
this Agreement and any other relevant agreements binding the
Consultant.  Consultant shall notify the Company of all other
consulting agreements which Consultant has entered into, or any consulting
services which Consultant may provide, to any third party.

    

    5.           Direction of Projects and
Inventions to the Company. Subject to the Consultant's obligations under
any confidentiality or other written obligations to third parties (including
academic institutions which Consultant is employed by), during the Term of this
Agreement, the Consultant will use his best efforts to disclose to the President
of the Company, on a confidential basis, technology and product opportunities
which come to the attention of the Consultant in the Field of Interest, and any
invention, improvement, discovery, process, formula or method or other
intellectual property relating to or useful in, the Field of Interest
(collectively "New
Discoveries"), whether or not patentable or copyrightable, and whether or
not discovered or developed by Consultant.

    

    6.           Inventions Discovered by the
Consultant While Performing Services Hereunder. The Consultant will
promptly and fully disclose to the President of the Company any invention,
improvement, discovery, process, formula, technique, method, trade secret, or
other intellectual property, whether or not patentable, whether or not
copyrightable (collectively, "Invention")
made, conceived, developed, or first reduced to practice by the Consultant,
either alone or jointly with others, while performing services hereunder. The
Consultant hereby assigns to the Company all of his right, title and interest in
and to any such Inventions. The Consultant will execute any documents necessary
to perfect the assignment of such Inventions to the Company and to enable the
Company to apply for, obtain, and enforce patents or copyrights in any and all
countries on such Inventions. The Consultant hereby irrevocably designates the
Secretary of the Company as his agent and attorney-in-fact to execute and file
any such document and to do all lawful acts necessary to apply for and obtain
patents and copyrights, and to enforce the Company's rights under this
paragraph. This Section 6 will survive the termination of this
Agreement.

    

    7.           Confidentiality.

    

    7.1           The
Consultant acknowledges that, during the course of performing his services
hereunder, the Company will be disclosing information to the Consultant, and the
Consultant will be developing information related to the Field of Interest,
Inventions, projects, products, potential customers, personnel, business plans,
and finances, as well as other commercially valuable information (collectively
"Confidential
Information"). The Consultant acknowledges that the Company's business is
extremely competitive, dependent in part upon the maintenance of secrecy, and
that any disclosure of the Confidential Information would result in serious harm
to the Company.  The Consultant agrees that the Confidential
Information will be used by the Consultant only in connection with consulting
activities hereunder, and will not be used in any way that is detrimental to the
Company.  The Consultant agrees not to disclose, directly or
indirectly, the Confidential Information to any third person or entity, other
than representatives or agents of the Company. The Consultant will treat all
such information as confidential and proprietary property of the
Company.  The term "Confidential
Information" does not include information that (i) is or becomes
generally available to the public other than by disclosure in violation of this
Agreement, (ii) was within the relevant party's possession prior to being
furnished to such party, (iii) becomes available to the relevant party on a
non-confidential basis, or (iv) was independently developed by the relevant
party without reference to the information provided by the
Company.  The Consultant may disclose any Confidential Information
that is required to be disclosed by law, government regulation or court order.
If disclosure is required, the Consultant will give the Company advance notice
so that the Company may seek a protective order or take other action reasonable
in light of the circumstances.  Upon termination of this Agreement,
the Consultant will promptly return to the Company all materials containing
Confidential Information as well as data, records, reports and other property,
furnished by the Company to the Consultant or produced by the Consultant in
connection with services rendered hereunder, together with all copies of any of
the foregoing. Notwithstanding such return, the Consultant shall continue to be
bound by the terms of the confidentiality provisions contained in this Section 7
for a period of two years after the termination of this Agreement.

    

    7.2           If
the Consultant has a conflict of interest, or potential conflict of interest,
with respect to any matter presented at a meeting of the SAB, he shall excuse
himself from the discussion of such matter and at the time of the execution of
this Agreement, Consultant shall disclose and describe all potential conflicts
of interest that may arise from the execution of this Agreement with respect to
prior engagements Consultant is a party to.

    

    7.3           The
attached Exhibit B Non-Disclosure Agreement shall be incorporated herein as if
it were a term of the same Agreement.

    

    8.           Freedom to
Publish.

    

    8.1           The
Company acknowledges the Consultant's obligation to disseminate new knowledge
and research findings. Notwithstanding the confidentiality provisions, or any
other provision, of this Agreement, the Consultant may publish and make oral
presentations of the results of the Consultant's work performed pursuant to this
Agreement under the terms set forth in this Section 8.

    

    8.2           The
Consultant acknowledges that publication or oral disclosure of any Invention or
other work prior to filing for patent or copyright protection could result in
the complete loss of any commercial value of the Consultant's research to the
Company, and/or the Consultant, as the case may be. The Consultant will provide
the Company with sufficient disclosure regarding Inventions owned by the Company
under Section 6 at least 90 days prior to publication to allow the Company to
evaluate such disclosure; Consultant will work with the Company to file patent
or copyright applications prior to disclosure or publication, or to modify such
publication if such disclosure regarding Inventions owned by the Company under
Section 6 would materially affect the business of the Company.

    

    9.           Use of Name. It is
understood that the name of the Consultant will appear in disclosure documents
required by securities laws, and in other regulatory, administrative filings and
public relations materials in the ordinary course of the Company's business. The
above-described uses will be deemed to be acceptable uses.

    

    10.           No Conflict: Valid and
Binding. The Consultant represents that neither the execution of this
Agreement nor the performance of the Consultant's obligations under this
Agreement will result in a violation or breach of any other agreement by which
the Consultant is bound. The Company represents that this Agreement has been
duly authorized and executed and is a valid and legally binding obligation of
the Company, subject to no conflicting agreements.

    

    11.           Notices. Any notice
provided under this Agreement shall be in writing and shall be deemed to have
been effectively given (i) upon receipt when delivered personally, (ii) one day
after sending when sent by private express mail service (such as Federal
Express), or (iii) 5 days after sending when sent by regular mail to the
following address:

    

    
      	
              In the case of the Company:

            	
              In the case of the
    Consultant:

            
	 
      	 
      
	
              Shrink
      Technologies, Inc.

            	
              Attention:
      Michelle Khine

            
	
              2038
      Corte del Nogal, Suite 110

            	
              mckhinester@gmail.com

            
	
              Carlsbad,
      California 92011

            	 
      

    

    

    or to
other such address as may have been designated by the Company or the Consultant
by notice to the other given as provided herein.

    

    12.           Independent Contractor:
Withholding. The Consultant will at all time be an independent
contractor, and as such will not have authority to bind the Company. The Parties
acknowledge that this Agreement is not a contract within the meaning of Section
2750 of the California Labor Code, and the Consultant is not an employee of the
Company for any purpose under the California Labor Code.  Consultant
will not act as an agent nor shall he be deemed to be an employee of the Company
for the purposes of any employee benefit program, unemployment benefits, or
otherwise. The Consultant recognizes that no amount will be withheld from his
compensation for payment of any federal, state, or local taxes and that the
Consultant has sole responsibility to pay such taxes, if any, and file such
returns as shall be required by applicable laws and regulations. Consultant
shall not enter into any agreements or incur any obligations on behalf of the
Company.

    

    13.           Assignment. Due to
the personal nature of the services to be rendered by the Consultant, the
Consultant may not assign this Agreement. The Company may assign all rights and
liabilities under this Agreement to a subsidiary or an affiliate or to a
successor to all or a substantial part of its business and assets without the
consent of the Consultant. Subject to the foregoing, this Agreement will inure
to the benefit of and be binding upon each of the heirs, assigns and successors
of the respective parties.

    

    14.           Severability. If any
provision of this Agreement shall be declared invalid, illegal or unenforceable,
such provision shall be severed and the remaining provisions shall continue in
full force and effect.

    

    15.           Remedies. The
Consultant acknowledges that the Company would have no adequate remedy at law to
enforce Sections 4, 5, 6 and 7 hereof. In the event of a violation by the
Consultant of such Sections, the Company shall have the right to obtain
injunctive or other similar relief, as well as any other relevant damages,
without the requirement of posting bond or other similar measures.

    

    16.           Governing Law; Entire
Agreement; Amendment. This Agreement shall be governed by the laws of the
State of California applicable to agreements made and to be performed within
such State, represents the entire understanding of the parties, supersedes all
prior agreements between the parties, and may only be amended in
writing.

    

    IN
WITNESS WHEREOF, the parties have executed this Agreement as of the date first
written above.

    

    Shrink
Technologies,
Inc.                                                           Consultant

    

    

    

    ____________________________                                         _____________________________

    By: Mark
L.
Baum                                                                           By:
Michelle Khine

    Its:
President                                                                                  
an individual

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    EXHIBIT
A

    

    

    Fields of
Interest

    

    The
Consultant has reviewed information provided by the Company and other
information which may be publicly available on the world-wide-web, and is
familiar with the specific research efforts and business projects that the
Company is engaged in and is actively pursuing.

    

    The
Company wishes to pursue a greater understanding of the durability and nature of
the polystyrene substrate it uses in various applications which have been
discussed with Consultant.  The Company also wishes to pursue new
methods to create nanostructures on the polystyrene substrates it presently
uses, and to find other materials which may enable similar efficiencies and
values to products and products classes as the Company believes it may
commercially offer through the use of polystyrene.

    

    Broadly,
the Company desires for Consultant to advance the Company’s technologies and
products, those which exist and those which may reasonably exist, for all
uses.

    

    Description of
Services

    

    Assist
management of the Company by:

    

    1.           Determining
the general scientific direction of the company;

    2.           Recruiting
of Scientific Advisory Board Members and Consultants to the
Company;

    3.           Recruiting
full-time management and scientific personnel to the Company;

    4.           Reviewing
the feasibility of the scientific goals of the Company and developing strategies
for achievingthem;

    5.           Identifying
and developing relationships with potential strategic partners;

    6.           Identifying,
reviewing and advising the Company, in a form (oral, writing or other) that is
generallyacceptable by scientists advising businesspersons in order to be
reasonably commercially useful, as to themost recent scientific advances in the
Field of Interest, as well as other scientific developments and intellectual
property in the Field of Interest; and

    7.           Providing
advice, support, theories, techniques and improvements in the Company's
scientific research andproduct development activities.

    

    

    Prior Engagements and
Potential Conflicts of Interest

    

    Name of
Company                                                                                                           Area
of ConsultationDC6940.pdf -- Converted by SEC Publisher 4.2, created by BCL Technologies Inc., for SEC Filing

	
Exhibit 10.41

DYNAVAX TECHNOLOGIES CORPORATION

MANAGEMENT CONTINUITY AND SEVERANCE AGREEMENT

	
Amended April 22, 2009

     This Management Continuity and Severance Agreement (the “Agreement”) is dated as of April 22, 2009, by and between Zbigniew
Janowicz, Chief Executive Officer and Managing Director, Rhein Biotech GmbH, Dynavax Technologies Corporation ("Employee"), and Dynavax Technologies Corporation, a Delaware corporation (the "Company" or “Dynavax”).

	
RECITALS

     A. It is expected that another company may from time to time consider the possibility of acquiring the Company or that a change in control may otherwise occur, with or
without the approval of the Company’s Board of Directors.  The Board of Directors recognizes that such consideration can be a distraction to Employee and can cause Employee to consider alternative employment opportunities. The Board of
Directors has determined that it is in the best interests of the Company to assure that the Company will have the continued dedication and objectivity of the Employee, notwithstanding the possibility, threat, or occurrence of a Change of Control (as
defined below) of the Company.

     B. The Company’s Board of Directors believes it is in the best interests of the Company to retain Employee and provide incentives to Employee to continue in the
service of the Company.

     C. The Board of Directors further believes that it is imperative to provide Employee with certain benefits upon a Change of Control and, under certain circumstances,
upon termination of Employee’s employment in connection with a Change of Control and independent of a Change of Control, which benefits are intended to provide Employee with encouragement to Employee to remain with the Company, notwithstanding
the possibility of a Change of Control or an employment termination.

     D. To accomplish the foregoing objectives, the Board of Directors has directed the Company, upon execution of this Agreement by Employee, to agree to the terms
provided in this Agreement.

     Now therefore, in consideration of the mutual promises, covenants, and agreements contained herein, and in consideration of the continuing employment of Employee by the Company, the parties hereto
agree as follows:

     1. At-Will Employment.  The Company and Employee acknowledge that Employee's employment is and shall continue to be at-will, as
defined under applicable law, and that Employee’s employment with the Company may be terminated by either party at any time for any or no reason. If Employee's employment terminates for any reason, Employee shall not be entitled to any
payments, benefits, damages, award, or compensation other than as provided in this Agreement, and as may otherwise be available in accordance with the terms of the

-1-

Company’s established employee plans and written policies at the time of termination.  The terms of this Agreement shall terminate upon the earlier of:  (i) the date on which Employee ceases to be employed by the Company,
other than as a result of an Involuntary Termination by the Company without Cause; or (ii) the date that all obligations of the parties hereunder have been satisfied. A termination of the terms of this Agreement pursuant to the preceding sentence
shall be effective for all purposes, except that such termination shall not affect the payment or provision of compensation or benefits on account of a termination of employment occurring prior to the termination of the terms of this Agreement. The
rights and duties created by this Section 1 may not be modified in any way except by a written agreement executed by the Chief Executive Officer (“CEO”) of the Company upon direction from the Board of Directors, or by the Chairman of the
Board in the case of the CEO.

	
2.      		
Benefits upon Termination of Employment.	
	 
	 	
(a) Termination for Cause. If Employee's employment is terminated for	
	 

Cause at any time, then Employee shall not be entitled to receive payment of any severance benefits. Employee will receive payment for all salary as of the date of Employee’s termination of employment and Employee’s
benefits will be continued under the Company's then existing benefit plans and policies in accordance with such plans and policies in effect on the date of termination and in accordance with applicable law.

     (b) Voluntary Resignation.  If Employee voluntarily resigns from the Company (the Employee’s employment does not end by
reason of Involuntary Termination), then Employee shall not be entitled to receive payment of any severance benefits.  Employee will receive payment for all salary as of the date of Employee’s termination of employment and Employee’s
benefits will be continued under the Company's then existing benefit plans and policies in accordance with such plans and policies in effect on the date of termination and in accordance with applicable law.

     (c) Involuntary Termination.  If Employee’s employment is terminated in an Involuntary Termination except following a
Change of Control, then Employee shall be entitled to: (1) a lump-sum cash severance payment equal to six (6) months of Employee’s then current annual base salary (less appropriate withholding deductions); (2) six (6) months of COBRA
Continuation paid by the Company if COBRA Continuation is elected; (3) an additional six (6) months vesting of Employee’s stock options to purchase the Company’s Common Stock; and (4) pursuant to the Dynavax Technologies Corporation 2004
Stock Incentive Plan, ninety

	
(90)      		
days to exercise vested options.	
	 
	 	
(d) Termination for Death or Disability. If Employee’s employment	
	 

terminates due to Employee’s death, then Employee’s beneficiary will receive any salary earned (less appropriate withholding deductions) through the date of termination of employment.  If Employee’s employment
terminates due to becoming disabled, all salaries due to Employee will be paid through the date of inception of Employee’s disability.

     In the event of termination for either death or disability, the exercise period of all vested options granted to Employee by the Company is extended to twelve (12) months from the date of termination
of employment.

-2-

	
3.      		
Benefits upon a Change of Control.	
	 
	 	
(a) Treatment of Stock Options. In the event of a Change of Control and the	
	 

Employee: (i) is offered and accepts a position with the New Company, or (ii) is not offered a position with the New Company that is comparable to the Employee’s position with the Company, then immediately prior to the
effective date of the Change of Control an additional two (2) years vesting of Employee’s stock options to purchase the Company’s Common Stock granted to Employee over the course of his employment with the Company and held by Employee on
the effective date of a Change of Control shall immediately vest on such date as to that number of shares that would have vested in accordance with the terms of the Stock Incentive Plan, as amended. “New Company,” as used in this Section
3(a), shall mean: (a) in the case of a Change of Ownership (as defined in Section 4(a)(i) below), the Company; (b) in the case of a Merger (as defined in Section 4(a)(ii) below), the surviving entity; or (c) in the case of a Sale of Assets (as
described in section 4(a)(ii) below), the purchaser of all or substantially all of the Company’s assets. For purposes of this Section 3(a), a position with the New Company shall be considered “comparable” to the Employee’s
position with the Company if such position would not form the basis for Employee’s voluntary termination of employment that would constitute an Involuntary Termination; provided, however, that for purposes of this Section 3(a) only, Section
4(c)(ii)(A) shall be applied in a manner that presumes that there is a material reduction of job duties or responsibilities if Employee’s position with the New Company is as part of a subsidiary or division of the New Company and the scope of
such duties or responsibilities is limited to such subsidiary or division and does not include the entire business operations of the New Company.

     (b) Severance.  In the event of a Change of Control and Employee’s employment is terminated for any reason, including
voluntary resignation, and such termination results in a “separation from service” within the meaning of Treasury Regulation Section 1.409A-1(h) without regard to any permissible alternative definition thereunder (a
“Termination”) within twenty-four (24) months following such Change of Control, Employee shall be entitled to:  (1) a lump-sum cash severance payment equal to twelve (12) months of Employee’s then current annual base salary, less
applicable withholding deductions, payable six (6) months after the date of the Termination; (2) a lump-sum cash payment equal to the Employee’s target incentive bonus of fifty percent (50%) (or such higher percentage then in effect under the
management incentive program or other similar bonus program) of the Employee’s then current annual base salary, less applicable withholding deductions, payable six (6) months after the date of the Termination; (3) twelve (12) months
Company-paid COBRA continuation coverage upon Employee’s election of COBRA Continuation Coverage; and (4) the extension of exercisability of all stock options to purchase the Company’s Common Stock for a period of three (3) years following
termination of employment (but in any event not beyond each option’s expiration date).

     4. Definition of Terms.  The following terms referred to in this Agreement shall have the following meanings:

     (a) Change of Control. “Change of Control” shall mean the occurrence of any of the following events:

-3-

     (i) Change of Ownership.  Any “Person” (as such term is used in Sections 13(d) and 14(d) of the Securities Exchange
Act of 1934, as amended) is or becomes the “Beneficial Owner” (as defined in Rule 13d-3 under said Act), directly or indirectly, of securities of the Company representing 50% or more of the total voting power represented by the
Company’s then outstanding voting securities; or

     (ii) Merger/Sale of Assets.  A merger or consolidation of the Company whether or not approved by the Board, other than a merger
or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity) at least
50% of the total voting power represented by the voting securities of the Company or such surviving entity outstanding immediately after such merger or consolidation, or the stockholders of the Company approve a plan of complete liquidation of the
Company or an agreement for the sale or disposition by the Company of all or substantially all of the Company’s assets.

     (b) Cause. “Cause” shall mean: (i) gross negligence or willful misconduct in the performance of Employee’s
duties to the Company, where such gross negligence or willful misconduct has resulted or is likely to result in substantial and material damage to the Company or its subsidiaries; (ii) repeated unexplained or unjustified absence from the Company;
(iii) a material and willful violation of any federal or state law; (iv) commission of any act of fraud with respect to the Company; or (v) conviction of a felony or a crime involving moral turpitude causing material harm to the standing and
reputation of the Company, in each case as determined in good faith by the Board.

     (c) Involuntary Termination.  “Involuntary Termination” shall mean:  (i) any termination by the Company other than
for Cause; or (ii) Employee’s voluntary termination following (A) a material reduction or change in job duties, responsibilities, and requirements inconsistent with the Employee’s position with the Company and the Employee’s prior
duties, responsibilities, and requirements, or a material change in the level of management to which the Employee reports; (B) any material reduction of Employee’s base compensation (other than in connection with a general decrease in base
salaries for most officers of the successor corporation); or (C) Employee’s refusal to relocate to a facility or location more than 35 miles from the Company’s current location. Notwithstanding the foregoing, an Involuntary Termination
pursuant to the foregoing clause (ii) shall only be considered to occur if (x) Employee provides written notice to the Company of the existence of the condition that forms the basis for such resignation within 90 days following its initial
existence; (y) upon such notice, the Company does not cure such condition within 30 days thereafter; and (z) Employee’s resignation occurs not later than 180 days after the occurrence of the condition giving rise to the resignation
right.

     5. Conflicts.  Employee represents that his performance of all the terms of this Agreement
will not breach any other agreement to which Employee is a party. Employee has not entered, and will not during the term of this Agreement enter, into any oral or written agreement in conflict with any of the provisions of this Agreement. Employee
further represents that he is entering into or has entered into an employment relationship with the Company of his own free will and that he has not been solicited as an employee in any way by the Company.

-4-

     6. Successors.  Any successor to the Company (whether direct or indirect and whether by purchase, lease, merger, consolidation,
liquidation, or otherwise) to all or substantially all of the Company's business and/or assets shall assume the obligations under this Agreement and agree expressly to perform the obligations under this Agreement in the same manner and to the same
extent as the Company would be required to perform such obligations in the absence of a succession. The terms of this Agreement and all of Employee's rights hereunder and thereunder shall inure to the benefit of, and be enforceable by, Employee's
personal or legal representatives, executors, administrators, successors, heirs, distributees, devisees, and legatees.

     7. Notice. Notices and all other communications contemplated by this Agreement shall be in writing and shall be deemed to have
been duly given when personally delivered or when mailed by U.S. registered or certified mail, return receipt requested and postage prepaid. Mailed notices to Employee shall be addressed to Employee at the home address that Employee most recently
communicated to the Company in writing. In the case of the Company, mailed notices shall be addressed to its corporate headquarters, and all notices shall be directed to the attention of its Secretary.

	
8.      		
Parachute Payments.	
	 
	 	
(a) If any payment or benefit Employee would receive pursuant to a Change of	
	 

Control from the Company or otherwise (“Payment”) would (i) constitute a “parachute payment” within the meaning of Section 280G of the Internal Revenue
Code of 1988, as amended (the “Code”), and (ii) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the “Excise Tax”), then such
Payment shall be equal to the Reduced Amount. The “Reduced Amount” shall be either (x) the largest portion of the Payment that would result in no portion of the Payment being subject to the Excise Tax, or (y) the largest portion, up to and
including the total, of the Payment, whichever amount, after taking into account all applicable federal, state and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in
Employee’s receipt of the greatest economic benefit notwithstanding that all or some portion of the Payment may be subject to the Excise Tax. If a reduction in payments or benefits constituting “parachute payments” is necessary so
that the Payment equals the Reduced Amount, reduction shall occur in a manner necessary to provide Employee with the greatest economic benefit. If more than one manner of reduction of payments or benefits necessary to arrive at the Reduced Amount
yields the greatest economic benefit, the payments and benefits shall be reduced pro rata.

     (b) The independent registered public accounting firm engaged by the Company for general audit purposes as of the day prior to the effective date of the event
described in Section 280G(b)(2)(A)(i) of the Code shall perform the foregoing calculations. If the independent registered public accounting firm so engaged by the Company is serving as accountant or auditor for the individual, entity or group
effecting such event, the Company shall appoint a nationally recognized independent registered public accounting firm to make the determinations required hereunder.  The Company shall bear all expenses with respect to the determinations by such
independent registered public accounting firm required to be made hereunder.  The independent registered public accounting firm engaged to make the determinations hereunder shall provide its calculations, together with detailed supporting
documentation, to the Company and Employee within thirty (30) calendar days after the date on which Employee’s right to a Payment is triggered (if requested at that time by the Company or

-5-

Employee) or such other time as requested by the Company or Employee.  Any good faith determinations of the independent registered public accounting firm made hereunder shall be final, binding and conclusive upon the Company and
Employee.

	
9.      		
Miscellaneous Provisions.	
	 
	 	
(a) No Duty to Mitigate. Employee shall not be required to mitigate the	
	 

amount of any payment contemplated by this Agreement (whether by seeking new employment or in any other manner), nor shall any such payment be reduced by any earnings that Employee may receive from any other source.

     (b) Waiver.  No provision of this Agreement shall be modified, waived, or discharged unless the modification, waiver, or
discharge is agreed to in writing and signed by Employee and by an authorized officer of the Company (other than Employee). No waiver by either party of any breach of, or of compliance with, any condition or provision of this Agreement by the other
party shall be considered a waiver of any other condition or provision or of the same condition or provision at another time.

     (c) Whole Agreement.  No agreements, representations, or understandings (whether oral or written and whether expressed or
implied) which are not expressly set forth in this Agreement have been made or entered into by either party with respect to the subject matter hereof, except as set forth in the Management Service Contract between Rhein Biotech GmbH and the Employee
dated January 17, 2005 (“Service Contract”). With the express exception of the Service Contract, this Agreement supersedes any agreement of the same title and concerning similar subject matter dated prior to the date of this Agreement, and
by execution of this Agreement both parties agree that any such predecessor agreement shall be deemed null and void. In the event Employee’s employment is involuntarily terminated under this Agreement and under the Service Contract, Employee
shall have the right to elect to receive severance pay and benefits, based on his then current compensation and benefits, either under the terms and conditions of this Agreement or of the Service Contract, at his sole discretion, upon written notice
to the Company. If Employee elects to receive severance pay and benefits under the terms of the Service Contract, any dispute regarding such election or any benefits due to the Employee under the Service Contract shall be governed by the laws of the
Federal Republic of Germany and resolved in the German courts.

     (d) Choice of Law.  The validity, interpretation, construction and performance of this Agreement shall be governed by the laws
of the State of California without reference to conflict of laws provisions.

     (e) Severability.  If any term or provision of this Agreement or the application thereof to any circumstance shall, in any
jurisdiction and to any extent, be invalid or unenforceable, such term or provision shall be ineffective as to such jurisdiction to the extent of such invalidity or unenforceability without invalidating or rendering unenforceable the remaining terms
and provisions of this Agreement or the application of such terms and provisions to circumstances other than those as to which it is held invalid or unenforceable, and a suitable and equitable term or provision shall be substituted therefore to
carry out, insofar as may be valid and enforceable, the intent and purpose of the invalid or unenforceable term or provision.

-6-

     (f) Arbitration. Any dispute or controversy arising under or in connection with this Agreement may be settled at the option of
either party by binding arbitration in the County of Alameda, California, in accordance with the rules of the American Arbitration Association then in effect before a single arbitrator.  The judgment may be entered on the arbitrator’s award in
any court having jurisdiction. Punitive damages shall not be awarded.

     (g) Legal Fees and Expenses.  The parties shall each bear their own expenses, legal fees, and other fees incurred in connection
with this Agreement. This means the Company pays its own legal fees in connection with this Agreement and the Employee is responsible for his own legal fees in connection with this Agreement. However, the arbitrator may award legal fees and expenses
in connection with any arbitration as deemed appropriate.

     (h) No Assignment of Benefits.  The rights of any person to payments or benefits under this Agreement shall not be made subject
to option or assignment, either by voluntary or involuntary assignment or by operation of law, including (without limitation) bankruptcy, garnishment, attachment, or other creditor’s process, and any action in violation of this Section 9(h)
shall be void.

     (i) Employment Taxes. All payments made pursuant to this Agreement will be subject to withholding of applicable income and
employment taxes.

     (j) Assignment by Company. The Company may assign its rights under this Agreement to an affiliate, and an affiliate may assign
its rights under this Agreement to another affiliate of the Company or to the Company; provided, however, that such assignee is the employer of the Employee. In the case of any such assignment, the term “Company” when used in a section of
this Agreement shall mean the corporation that actually employs the Employee except that the term “Company” shall continue to mean Dynavax Technologies Corporation with regard to the definition of a Change of Control.

     (k) Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which
together will constitute one and the same instrument.

	
[SIGNATURE PAGE FOLLOWS]

-7-

The parties have executed this Agreement on the date first written above.

DYNAVAX TECHNOLOGIES CORPORATION

	
By: /s/ Dino Dina

Title: President and Chief Executive Officer

Address: 2929 Seventh Street

Suite #100

Berkeley, CA 94710

	
ZBIGNIEW JANOWICZ

	
Signature: 
		
 		
/s/ Zbigniew Janowicz 
	
	
		
		

	
	
 
	
	
Address: 
		
 		
        Eichsfelder Str. 11 
	
	
 
		
 		
        40595 Düsseldorf 
	
	
 
		
 		
        Germany 
	

-8-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00159-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00159-of-00352.parquet"}]]